Cellcolabs names Vincent Metzler as new CEO after four-month vacancy
What's the deal? CellcolabsDealroom has a profile for this one. Try Dealroom →, a Swedish stem cell company backed by a roster of heavyweight Nordic tech investors, has appointed Vincent Metzler as its new chief executive officer. The role had been vacant since late January, when previous CEO Mattias Bernow abruptly departed and Petter Hellman stepped in as interim leader.
Metzler brings experience from several research-based companies. "The company combines strong scientific capability with industrial production capacity and a vision with significant potential," he said in a press release.
Cellcolabs grows stem cells for use in healthcare and runs clinical trials in the Bahamas exploring stem cell applications. Its investor list reads like a who's who of Nordic tech: Norrsken LauncherDealroom has a profile for this one. Try Dealroom →, Titian Capital, Avito co-founders Jonas NordlanderDealroom has a profile for this one. Try Dealroom → and Filip EngelbertDealroom has a profile for this one. Try Dealroom →, Evolution Gaming founders Fredrik ÖsterbergDealroom has a profile for this one. Try Dealroom → and Jens von BahrDealroom has a profile for this one. Try Dealroom →, Mojang founder Carl Manneh, Kry founder Johannes Schildt, angel investor Susanna Campbell, and well-known profiles Ash Pournouri and Sven Hagströmer.
Why now? The company has been without a permanent CEO for roughly four months. Board chair Maria Rankka pointed to "encouraging progress in our clinical trials and growing potential in osteoarthritis and other selected indications" as reasons for optimism — suggesting the company wants stable leadership as it enters its next phase.
What could go wrong? Stem cell therapies face significant regulatory hurdles in most major markets. Running clinical trials in the Bahamas rather than in the EU or US could raise questions about the regulatory pathway to commercialisation. Leadership instability — two CEO changes in a matter of months — is also a yellow flag for investors watching closely.
The signal: Cellcolabs is classified as a "breakout" stage company on Dealroom, suggesting it has moved beyond the earliest startup phase — yet the months-long leadership vacuum hints that operational maturity has lagged behind investor enthusiasm. The heavy concentration of Nordic tech founders on the cap table, rather than specialist life-science investors, underscores how longevity and cell therapy have become a conviction bet for the tech elite, even as the sector's regulatory and commercial risks remain largely unresolved.
Read more: Breakit
